Group B streptococcal infections in the newborn infant and the potential value of maternal vaccination

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 11, 2015, Pages 1387-1399

  Berardi, Alberto ^a   Cattelani, Chiara ^a   Creti, Roberta ^b   Berner, Reinhard ^c   Pietrangiolillo, Zaira ^a   Margarit, Immaculada ^d   Maione, Domenico ^d   Ferrari, Fabrizio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d GSK   (Italy)

Author keywords

Early onset disease; Group B Streptococcus; intrapartum antibiotic prophylaxis; late onset disease; newborn infant; pregnancy; prevention; sepsis; vaccine

Indexed keywords

BACTERIAL ANTIGEN; STREPTOCOCCUS VACCINE; AMPICILLIN; ANTIINFECTIVE AGENT; PENICILLIN DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; BIOINFORMATICS; CLINICAL FEATURE; DRUG COST; DRUG EFFICACY; GROUP B STREPTOCOCCAL INFECTION; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; MATERNAL VACCINATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; ONSET AGE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRENATAL SCREENING; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR; SECONDARY PREVENTION; VACCINATION; VERTICAL TRANSMISSION; FEMALE; INFANT; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; PREVENTION AND CONTROL; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

AMPICILLIN; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PENICILLINS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; RISK FACTORS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 84945484202     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1079126     Document Type: Review

References (107)

1. Edwards MS, Nizet V, Group B. Streptococcal infections. In: Remington JS, Klein JO.,. editors. Infectious diseases of the fetus and newborn infant. 8th edition. Elsevier Saunders; Philadelphia: 2016. p. 411-56
2. Centers for disease control and prevention. 2013. Active bacterial core surveillance (ABCs) report emerging infections program network group B streptococcus, 2013-provisional. Available from: www.cdc.gov/abcs/reports-findings/survreports/gbs13.pdf. [Last accessed 3 April 2015]
3. Schuchat A. Epidemiology of group B streptococcal disease in the US: shifting paradigms. Clin Microbiol Rev 1998; 11: 497-513
4. Phares CR, Lynfield R, Farley MM, et al. Active bacterial core surveillance/emerging infections program network. Epidemiology of invasive group B streptococcal dis-ease in the US, 1999-2005. J Am Med Assoc 2008; 299: 2056-65
5. Regan JA, Klebanoff MA, Nugent RP, et al. Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol 1996; 174: 1354-60
6. Melin P, Efstratiou A. Group B streptococcal epidemiology and vaccine needs in developed countries. Vaccine 2013; 28: 31-42
7. Yancey MK, Schichat A, Brown LK, et al. The accuracy of late antenatal screening cultures in prediciting genital group B streptococcal colonization at delivery. Obstet Gynecol 1996; 88: 811-15
8. Edwards RK, Clark P, Duff P. Intrapartum antibiotic prophylaxis 2: positive predictive value of antenatal group B streptococci cultures and antibiotic susceptibility of clinical isolates. Obstet Gynecol 2002; 100: 540-4
9. Valkenburg-van den Berg AW, Sprij AJ, Oostvogel PM, et al. Prevalence of colonisation with group B streptococci in pregnant women of a multiethnic population in The Netherlands. Eur J Obstet Gynecol Reprod Biol 2006; 124: 178-83
10. El Helali N, Nguyen JC, Ly A, et al. Diagnostic accuracy of a rapid real-time polymerase chain reaction assay for universal intrapartum group B streptococcus screening. Clin Infect Dis 2009; 49: 417-23
11. Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics 2005; 115: 1240-6
12. Pulver LS, Hopfenbeck MM, Young PC, et al. Continued early onset group B streptococcal infections in the era of intrapartum prophylaxis. J Perinatol 2009; 29: 20-5
13. Stoll BJ, Hansen NI, Sánchez PJ, et al. Early onset neonatal sepsis: the burden of group B streptococcal and E. coli disease continues. Pediatrics 2011; 127: 817-26
14. Berardi A, Lugli L, Rossi C, et al. Impact of perinatal practices for early-onset group-B streptococcal disease prevention. Pediatr Infect Dis J 2013; 32: 265-71
15. El Helali N, Giovangrandi Y, Guyot K, et al. Cost and effectiveness of intrapartum group B streptococcus polymerase chain reaction screening for term deliveries. Obstet Gynecol 2012; 119: 822-9
16. Berardi A, Rossi C, Guidotti I, et al. Factors associated with intrapartum transmission of group B streptococcus. Pediatr Infect Dis J 2014; 33: 1211-15
17. Bergeron MG, Danbing K. New DNA-based PCR approaches for rapid real-time detection and prevention of group B streptococcal infections in newborns and pregnant women. Reprod Medi Rev 2004; 11: 25-41
18. Di Renzo GC, Melin P, Berardi A, et al. Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Matern Fetal Neonatal Med 2014; 27: 1-17
19. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 2012; 379: 547-56
20. Springman AC, Lacher DW, Wu G, et al. Selection, recombination, and virulence gene diversity among group B streptococcal genotypes. J Bacteriol 2009; 191: 5419-27
21. Sørensen UB, Poulsen K, Ghezzo C, et al. Emergence and global dissemination of host-specific Streptococcus agalactiae clones. MBio 2010; 1: e00178-10
22. Da Cunha V, Davies MR, Douarre PE, et al. Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline. Nat Commun 2014; 5: 4544
23. Landwehr-Kenzel S, Henneke P. Interaction of streptococcus agalactiae and cellular innate immunity in colonization and disease. Front Immunol 2014; 5: 519
24. Tazi A, Disson O, Bellais S, et al. The surface protein HvgA mediates Group B streptococcus hypervirulence and meningeal tropism in neonates. J ExpMed 2010; 207: 2313-22
25. Berner R, Niemeyer CM, Leititis JU, et al. Plasma levels and gene-expression of G-CSF, TNF-alpha, IL-1beta, IL-6, IL-8, and sICAM-1 in neonatal early-onset sepsis. Pediatr Res 1998; 44: 469-77
26. Berner R. Significance, management and prevention of Streptococcus agalactiae infection during the perinatal period. Expert Rev Anti Infect Ther 2004; 2: 427-37
27. Fujieda M, Aoyagi Y, Matsubara K, et al. L-ficolin and capsular polysaccharide-specific IgG in cord serum contribute synergistically to opsonophagocytic killing of serotype III and V group B streptococci. Infect Immun 2012; 80: 2053-60
28. Benitz WE, Gould JB, Druzin ML. Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Pediatrics 1999; 103: 77
29. Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B Streptococcal disease. Revised guidelines from CDC. 2010. MMWR Recomm Rep 2010; 59: 1-36
30. Heath PT, Balfour G, Weisner AM, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days. Lancet 2004; 363: 292-4
31. Antony BF, Okada DM, Hobel CJ. Epidemiology of the group B streptococcus: Maternal and nosocomial sources for infant acquisitions. J Pediatr 1979; 95 (3): 431-6
32. Royal college of obstetricians and gynaecologists: Guidelines. The prevention of early onset neonatal group B streptococcal disease. Green-top Guideline N 36. 2nd Edition. Available from: www.rcog.org.uk/files/rcogcorp/GTG36-GBS.pdf. [Last accessed 1-13 July 2012]
33. Bromberger P, Lawrence JM, Braun D, et al. The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. Pediatrics 2000; 106: 244-50
34. Berardi A, Lugli L, Rossi C, et al. Intrapartum antibiotic prophylaxis failure and group-B streptococcus early-onset disease. J Matern Fetal Neonatal Med 2011; 24: 1221-4
35. Mc Cracken GH Jr. Group B streptococci: the new challenge in neonatal infections. J Pediatr 1973; 82: 703-6
36. Berardi A, Rossi C, Lugli L, et al. Group B Streptococcus late-onset disease: 2003-2010. Pediatrics 2013; 131: 361-8
37. Paredes A, Wong P, Mason EO Jr, et al. Nosocomial transmission of group B Streptococci in a newborn nursery. Pediatrics 1977; 59: 679-82
38. Barbadoro P, Marigliano A, Savini S, et al. Group B Streptococcal sepsis: an old or ongoing threat? Am J Infect Control 2011; 39: 45-8
39. Filleron A, Lombard F, Jacquot A, et al. Group B streptococci in milk and late neonatal infections: an analysis of cases in the literature. Arch Dis Child Fetal Neonatal Ed 2014; 99: 41-7
40. Berardi A, Rossi C, Creti R, et al. Group B streptococcal colonization in 160 mother-baby pairs: a prospective cohort study. J Pediatr 2013; 163: 1099-104
41. Lin FY, Weisman LE, Troendle J, et al. Prematurity is the major risk factor for late-onset group B streptococcus disease. J Infect Dis 2003; 188: 267-71
42. Lanari M, Serra L, Cavrini F, et al. Late-onset group B streptococcal disease by infected mothers milk detected by polymerase chain reaction. New Microbiol 2007; 30: 253-4
43. Fluegge K, Greiner P, Berner R. Late onset group B streptococcal disease manifested by isolated cervical lymphadenitis. Arch Dis Child 2003; 88: 1019-20
44. Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 2008; 27: 1057-64
45. Penã BM, Harper MB, Fleisher GR. Occult bacteremia with group B streptococci in an outpatient setting. Pediatrics 1998; 102: 67-72
46. Fluegge K, Siedler A, Heinrich B, et al. Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics 2006; 117: 1139-45
47. Libster R, Edwards KM, Levent F, et al. Long-term outcomes of group B streptococcal meningitis. Pediatrics 2012; 130: 8-15
48. Ohlsson A, Shah VS. Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev 2013; 1: CD007467
49. Rodriguez-Granger J, Alvargonzalez JC, Berardi A, et al. Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project. Eur J Clin Microbiol Infect Dis 2012; 31: 2097-104
50. Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early onset group B streptococcal disease in neonates. N Engl J Med 2002; 347: 233-9
51. Bekker V, Bijlsma MW, van de Beek D, et al. Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis 2014; 14: 1083-9
52. Lamagni TL, Keshishian C, Efstratiou A, et al. Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991-2010. Clin Infect Dis 2013; 57: 682-8
53. Berardi A, Lugli L, Baronciani D, et al. GBS Prevention working group of Emilia-Romagna. Group B streptococcus early-onset disease in Emilia-Romagna: review after introduction of a screening-based approach. Pediatr Infect Dis J 2010; 29: 115-21
54. Brady MT, Polin RA. Prevention and management of infants with suspected or proven neonatal sepsis. Pediatrics 2013; 132: 166-8
55. Benitz WE, Wynn JL, Polin RA. Reappraisal of guidelines for management of neonates with suspected early-onset sepsis. J Pediatr 2015; 166: 1070-4
56. Ottolini MC, Lundgren K, Mirkinson LJ, et al. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. Pediatr Infect Dis J 2003; 22: 430-4
57. Glasgow TS, Speakman M, Firth S, et al. Clinical and economic outcomes for term infants associated with increasing administration of antibiotics to their mothers. Paediatr Perinat Epidemiol 2007; 21: 338-46
58. Flidel-Rimon O, Galstyan S, Juster-Reicher A, et al. Limitations of the risk factor based approach in early neonatal sepsis evaluations. Acta Paediatr 2012; 101: 540-4
59. National institute for health and clinical excellence. Antibiotics for early-onset neonatal infection: antibiotics for the prevention and treatment of early-onset neonatal infection. (CG102). London: NICE; 2012. Available from: http://guidance.nice.org.uk/CG149/Guidance/pdf/English. [Last accessed 13 September 2013]
60. Mukhopadhyay S, Eichenwald EC, Puopolo KM. Neonatal early-onset sepsis evaluations among well-appearing infants: projected impact of changes in CDC GBS guidelines. J Perinatol 2013; 33: 198-205
61. Escobar GJ, Li DK, Armstrong MA, et al. Neonatal sepsis workups in infants >/=2000 grams at birth: A population-based study. Pediatrics 2000; 106: 256-63
62. Cantoni L, Ronfani L, Da Riol R, et al. Physical examination instead of laboratory tests for most infants born to mothers colonized with group B Streptococcus: support for the Centers for Disease Control and Preventions 2010 recommendations. J Pediatr 2013; 163: 568-73
63. Berardi A, Fornaciari S, Rossi C, et al. Safety of physical examination alone for managing well-appearing neonates ≥35 weeks gestation at risk for early-onset sepsis. J Matern Fetal Neonatal Med 2014; 10: 1-5
64. Dahesh S, Hensler ME, Van Sorge NM, et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 2008; 52: 2915-18
65. Kimura K, Suzuki S, Wachino J, et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008; 52: 2890-7
66. Wang P, Tong JJ, Ma XH, et al. Serotypes, Antibiotic Susceptibilities, and multi-locus sequence type profiles of streptococcus agalactiae isolates circulating in Beijing, China. PLoS One 2015; 10: e0120035
67. Imperi M, Gherardi G, Berardi A, et al. Invasive neonatal GBS infections from an area-based surveillance study in Italy. Clin Microbiol Infect 2011; 17: 1834-9
68. Mercer BM, Carr TL, Beazley DD, et al. Antibiotic use in pregnancy and drug-resistant infant sepsis. Am J Obstet Gynecol 1999; 181: 816-21
69. Schrag SJ, Hadler JL, Arnold KE, et al. Risk factors for invasive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use. Pediatrics 2006; 118: 570-6
70. Al-Hasan MN, Lahr BD, Eckel-Passow JE, et al. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother 2009; 64: 169-74
71. Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118: 511-21
72. Sarkar S, Bhagat I, Hieber S, et al. Can neutrophil responses in very low birth weight infants predict the organisms responsible for late-onset bacterial or fungal sepsis? J Perinatol 2006; 26: 501-5
73. Deshmukh HS, Liu Y, Menkiti OR, et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat Med 2014; 20: 524-30
74. Kuppala VS, Meinzen-Derr J, Morrow AL, et al. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr 2011; 159 (5): 720-5
75. Shakib JH, Korgenski K, Sheng X, et al. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr 2013; 163: 1422-6
76. Munoz FM, Ferrieri P. Group B streptococcus vaccination in pregnancy: Moving toward a global maternal immunization program. Vaccine 2013; 31: 46-51
77. Rasmussen SA, Watson AK, Kennedy ED, et al. Vaccines and pregnancy: Past, present, and future. Semin Fetal Neonatal Med 2014; 19: 161
78. Omer SB, Goodman D, Steinhoff MC, et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med 2011; 8 (5): e1000441
79. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008; 359: 1555-64
80. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014; 384: 1521-8
81. Mc Quaid F, Jones C, Stevens Z, et al. Attitudes towards vaccination against group B streptococcus in pregnancy. Arch Dis Child 2014; 99: 700-1
82. Dempsey AF, Pyrzanowski J, Donnelly M, et al. Acceptability of a hypothetical group B strep vaccine among pregnant and recently delivered women. Vaccine 2014; 32: 2463-8
83. Rubens CE, Wessels MR, Heggen LM, et al. Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci USA 1987; 84: 7208-12
84. Baker CJ, Kasper L., Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med, 1976, 294, 753-6
85. Baker CJ, Kasper DL, Tager IRAB, et al. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B streptococcus. J Clin Invest 1977; 59: 810-18
86. Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B streptococcus in infant infection. Pediatrics 1981; 68: 544-9
87. Lin FY, Weisman LE, Azimi PH, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004; 190: 928-34
88. Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179: 142-50
89. Baker CJ, Rench MA, Fernandez M, et al. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003; 188: 66-73
90. Baker CJ, Paoletti LC, Rench MA, et al. Immune response of healthy women to two different type V group B streptococcal capsular polysaccharide-protein conjugate vaccines. J Infect Dis 2004; 189: 1103-12
91. Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis 2014; 209: 781-8
92. Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B Streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996; 98: 2308-14
93. Oster G, Edelsberga J, Hennegana K, et al. Prevention of group B streptococcal disease in the first 3 months of life: Would routine maternal immunization during pregnancy be cost-effective? Vaccine 2014; 32: 4778-85
94. Slobod K. Communication at XIX Lancefield International Symposium 9-12 November 2014 Buenos Aires, Argentina
95. Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early-and late-onset invasive disease in young-infants. Vaccine 2013; 31: 52-7
96. Larsson C, Holmgren J, Lindahl G, et al. Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection. Infect Immun 2004; 72 (2): 1184-7
97. Martin D, Rioux S, Gagnon E, et al. Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun 2002; 70: 4897-901
98. Cheng Q, Debol S, Lam H, et al. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B streptococci from lungs of infected mice. Infect Immun 2002; 70: 6409-15
99. Maione D, Margarit I, Rinaudo C.D, et al. Identification of a universal group B Streptococcus vaccine by multiple genome screen. Science 2005; 309: 148-50
100. Lauer P, Rinaudo C.D, Soriani M, et al. Genome analysis reveals pili in Group B Streptococcus. Science 2005; 309: 105
101. Rosini R, Rinaudo C.D, Soriani M, et al. Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol 2006; 61: 126-41
102. Telford J.L, Barocchi M.A, Margarit I, et al. Pili in Gram-positive pathogens. Nat Rev Microbiol 2006; 4: 509-19
103. Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009; 199: 108-15
104. Nuccitelli A, Cozzi R, Gourlay LJ, et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci USA 2011; 108: 10278-83
105. Kreikemeyer B, Gamez G, Margarit I, et al. Genomic organization, structure, regulation and pathogenic role of pilus constituents in major pathogenic streptococci and enterococci. Int J Med Microbiol 2011; 30: 240-51
106. Nilo A, Morelli L, Passalacqua I, et al. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation. ACS Chem Biol 2015. [Epub ahead of print]
107. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the US, 2005-2008. Pediatr Infect Dis J 2011; 30: 937-41